Prof David Argyle
Vice Principal and Head of College of Medicine & Veterinary, College of Medicine and Veterinary Medicine
Contact details
Address
- Street
-
The Royal (Dick) School of Veterinary Studies
Easter Bush Campus
Midlothian - City
- Post code
- EH25 9RG
Availability
Willingness to take Ph.D. students: Yes
Background
David Argyle is a graduate of Veterinary Medicine and Surgery from the University of Glasgow. He gained his PhD in Immunology and Oncology from the same faculty.
He has served as a clinical academic for the universities of Glasgow, Wisconsin-Madison and Edinburgh. He is an RCVS and European-recognised specialist in veterinary oncology and his major interests are cancer biology and comparative oncology.
In 2011, he was appointed William Dick chair of Veterinary Clinical Studies and Dean of Veterinary Medicine at The Royal (Dick) School of Veterinary Studies. In 2022, he was appointed to be Vice Principal and Head of College of Medicine and Veterinary Medicine at the University of Edinburgh.
He is a Fellow of the Royal College of Veterinary Surgeons, Fellow of the Royal Society of Edinburgh and a Fellow of the Royal Society for the Arts.
Collaborative Activity
Professor Ted Hupp
Professor Steve McLaughlin (Heriot-Watt University)
Professor Mark Bradley
Professor Andy Mount
Professor Ian Kunkler
Dr. Simon Langdon
Professor Joyce Tait (Innogen)
Dr. Jan Mol (Utrecht)
Qualifications
Doctor of Philosophy (PhD), University of Glasgow Cloning, Sequencing, Expression and Characterization of Feline Interferon-Gamm Bachelor of Veterinary Medicine & Surgery, University of Glasgow
Professional Qualifications
Diplomate of the European College of Veterinary Internal Medicine, DECVIM-CA (Oncology) Member of the Royal College of Veterinary Surgeons (Register Index Number: 6191897), MRCVS
Responsibilities & affiliations
Head of School
Research summary
Mechanistic studies into canine disease, specifically the focus of my research is comparative cancer biology. This involves studies on the stem cell basis of cancer through to the translation of new therapeutics into clinical development.